-66%

est. 2Y upside i

HealthcareSeries B

Rebuilding healthcare with AI at the core

Rank

#2222

Sector

Healthcare Technology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Akido Labs presents a moderate upside opportunity for a job seeker, driven by its innovative AI-enabled care model and strong growth potential in a large TAM.

Last updated: March 10, 2026

Bull (15%)+250%

Akido Labs' ScopeAI platform achieves widespread adoption, significantly increasing clinical capacity and patient volume across its Akido Care network and partner organizations. Strategic partnerships with major healthcare systems expand its reach into new markets, driving revenue to over $500M and justifying a $1.19B+ valuation, a 3.5x increase from its current valuation.

Base (45%)+75%

Akido Labs continues to grow steadily, expanding its Akido Care network and securing additional contracts with government agencies and healthcare providers. While facing strong competition from incumbents, its niche in underserved populations and integrated AI-enabled care model allows for consistent revenue growth, leading to an exit valuation of approximately $595M.

Bear (40%)-70%

Dominant incumbents like Epic and Oracle Cerner aggressively integrate similar AI capabilities into their EHR systems, commoditizing Akido's core offerings. Regulatory hurdles and slower-than-expected adoption in new markets limit growth, leading to a down round or acquisition at a valuation of $102M, effectively wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

32%

Investors hold $109M in liquidation preferences, meaning common stock holders would receive little to nothing in an exit below this amount, and significantly reduced returns up to the current $340M valuation.

Dilution Risk

moderate

As a Series B company with moderate capital intensity, future funding rounds are likely, which could lead to additional dilution for existing equity holders.

Secondary Liquidity

limited

There is no indication of active formal secondary markets or tender offers, though limited informal secondary transactions might occur.

View all 57 open roles at Akido Labs →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Akido Labs's data — designed to show you've done your homework.

  • 1

    “Given the significant incumbent threat from companies like Epic, Oracle Cerner, and Google integrating AI into their platforms, how does Akido Labs plan to differentiate and defend its market position over the next 2-3 years, especially with ScopeAI?”

  • 2

    “With Akido's hybrid revenue model and the strategic pivot to a full-stack provider, what are the key metrics the company is prioritizing to demonstrate scalable and profitable growth, particularly in expanding the Akido Care network and ScopeAI adoption?”

  • 3

    “Considering the Series B funding and the current valuation, what is the company's anticipated timeline for a liquidity event, and how does Akido Labs plan to manage potential future dilution for employees holding equity?”

Community

Valuation Sentiment

Our model estimates -66% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.